Lithium cocrystal

N/A

Report date: 2026/04/21 20:00:18

Base Information

Drug NameLithium cocrystal
Drug Alias NameLithium salicylate/L-proline cocrystalLiProSalAL-001(Alzamend Neuro)
ClassificationSmall molecules
Mechanisms of ActionNeurons modulatorsNitric oxide synthesis inhibitor
TargetsNot applicable
Therapy Area/IndicationsBipolar I DisorderStress Disorders, Post-TraumaticDepressive Disorder, Major +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of South Florida
China Registration ClassN/A

Develop Information

Active CompaniesMassachusetts General Hospital Cancer CenterAlzamend Neuro IncUniversity Of South Florida +[4] 
Inactive CompaniesN/A
Active IndicationsBipolar I DisorderStress Disorders, Post-TraumaticDepressive Disorder, Major +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A